Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and Distinguished Portfolio

RARITAN, N.J., November 3, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson are committed to redefining treatment outcomes in the hematology setting and today announced that abstracts from more than 50 company-sponsored studies, plus more than 20 investigator-initiated studies, will be presented at the American Society of Hematology (ASH) Annual Meeting in New Orleans from December 10-13, 2022. Janssen’s commitment to advancing an innovative portfolio of therapies for healthcare professionals and patients is evidenced through more than 70 presentations that span clinical studies and real-world data. In addition, this year’s ASH press program will feature data from the Phase 1/2 MonumenTAL-1 talquetamab (GPRC5DxCD3 bispecific antibody) study in relapsed or refractory multiple myeloma (RRMM), and the Plenary Scientific Session will highlight results from an investigator-initiated study of IMBRUVICA® (ibrutinib) in mantle cell lymphoma (MCL) on December 11.“Janssen’s robust presence at ASH reflects a long-term commitment to discover and develop innovative, transformative therapies for patients with cancer,” said Peter Lebowitz, M.D., Ph.D., Global Therapeutic Area Head, Oncology, Janssen Research & Development, LLC. “Recognizing the significant unmet needs that continue to persist in the treatment of hematologic malignances, we have never been more determined and dedicated in our mission to deliver cures.”“In addition to ...

Source: Johnson and Johnson - November 3, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news